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Implementation of Biocatalysis in
Continuous Flow for the Synthesis of
Small Cyclic Amines
Eimear Hegarty and Francesca Paradisi*
Abstract: Significant progress has been made in establishing transaminases as robust biocatalysts for the green
and scalable synthesis of a diverse range of chiral amines.[1] However, very few examples on the amination of
small cyclic ketones have been reported.[2] Cyclic ketones are particularly challenging for transaminase enzymes
because they do not display the well-defined small and large substituent areas that are characteristic for the bio-
catalytic mechanism. In this work, we exploited the broad substrate scope of the (S)-selective transaminase from
Halomonas elongata (HeWT) to develop an efficient biocatalytic system in continuous flow to generate a range
of small cyclic amines which feature very often in pharmaceuticals and agrochemicals.[3] Tetrahydrofuran-3-one
and other challenging prochiral ketones were rapidly (5–45 min) transformed to their corresponding amines with
excellent molar conversion (94–99%) and moderate to excellent ee.
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Introduction
The asymmetric reduction of prochiral ketones with the for-
mation of enantiomerically pure molecules is a fundamentally
important reaction in synthetic organic chemistry and medicinal
chemistry. These architectures find application in a wide range
of fields, as well as serving as key intermediates in the synthesis
of several pharmaceutical compounds. For example, the enantio-
pure chiral alcohol derived from tetrahydrofuran-3-one is used
for the synthesis of the HIV inhibitor amprenavir and its prodrug
form fosamprenaivr, while the amine analogue forms an integral
structural feature in selective high affinity adenosine A1 recep-
tor agonists, which have received considerable attention for their
antiarrhythmic activity.[4,5] Chiral manmade transition metal cat-
alysts and certain organocatalysts have been applied successfully
in ketone reductions.[6,7]However, in all of these approaches, high
enantioselectivty can be achieved only when the α and α'-sub-
stituents flanking the carbonyl functionality differ sterically.
Spatially symmetric ketones, such as tetrahydrofuran-3-one and
related substrates are particularly challenging in this regard, with
asymmetric reductions typically resulting in poor enantioselec-
tivities irrespective of the catalyst. To overcome these challenges,
Pfizer developed a five-step process to obtain the chiral alcohol
(R)-tetrahydrothiophene-3-ol which is a key component in the po-
tent antibiotic sulopenem.[8]While the desired alcohol is generally
obtained in good yields and high optical purity (96-98% ee) using
this approach, the synthesis involves hazardous conditions (diaz-
otization in step 1), a sensitive reagent (BH
3
·dimethylsulfide in
step 2), high energy intermediates (epoxides in steps 3 and 4) and
a noxious reagent (Na
2
S in step 5) (Scheme 1).
The uptake of biocatalysis as a useful tool for asymmetric
synthesis has led to the development of a number of complemen-
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Scheme 1. Synthesis of (R)-tetrahydrothiophene-3-ol starting from
l-aspartic acid.[8]
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PfTA, however the ee was again low in both cases, at 66% and
20% respectively. Interestingly, the use of compounds with a me-
thyl group at the 4-position (3a, 4a) gave significantly higher ee
values, which suggests that the methyl group may help orientate
the molecule in the active site in such a way that the formation of
the (S)-enantiomer is favoured. To further probe this hypothesis,
the crystal structure of HeWT (PDB: 6GWI) was used to dock
selected compounds (1a and 4a) from our panel into its active
site.[14]
Docking Analysis of Ketones 1a and 4a in the Active
Site of HeWT
HeWT is a homodimer, with an active site positioned at the
interface of the monomers and a substrate binding region that is
composed of a small and a large binding pocket. This character-
istic architecture typically limits the substrate scope of wild-type
ω-TAs to ketones bearing at least one small substituent, not ex-
ceeding that of a methyl group. Our molecular docking studies
have confirmed that small cyclic ketones are particularly challeng-
ing for HeWT as they evidently do not display the well-defined
small and large substituents that are typically a prerequisite for the
transaminase biocatalytic mechanism.[19] Fig. 1(left) shows the
docking of tetrahydrofuran-3-one (1a) in the active site ofHeWT.
In this case, the tetrahydrofuranyl ring oxygen appears to form
a hydrogen bond with the side chain of W56. This interaction
anchors the substrate in the active site such that the reductive am-
ination of the carbonyl is favoured. In the case of 1-methyl-3-pip-
eridone (4a) the docking displaying the most favourable score
places the substrate in a position that is further away from the PLP
cofactor (3.23Å, Fig. 1(right)) when compared to 1a (2.70Å, Fig.
1(left)). Interestingly, the substrate is positioned in the vicinity of
the large binding pocket. The high stereoselectivity achieved by
HeWT in the case of 4b, suggests that this orientation and binding
mode favours the formation of the (S)-enantiomer.
Continuous Flow Synthesis of Small Cyclic Amines
The promising results obtained with HeWT in batch mode led
us to explore the possibility of carrying out continuous reactions
as an alternative strategy for the scale-up synthesis of the target
amines. Compared to batch processes, performing reactions in
continuous flow mode offer several benefits including better pa-
rameter control, reduced reaction times, improved yields and re-
cycling of unreacted reagents.[20] Specifically with respect to bio-
catalytic transformations, continuous flow can also offer addition-
al benefits such as reduced enzyme inhibition through continuous
product removal and facile downstream processing.[21]HeWTwas
therefore covalently immobilized onto a commercially available
epoxy support as previously reported.[13]With an enzyme loading
of 5mg/g resin, the resulting biocatalyst displayed an activity of
38 U/g resin. A continuous flow reactor, packed with immobi-
lized-HeWT,was subsequently set up and optimized for the prepa-
ration of 1b. The substrate loading in this case was increased to 50
mM, while the amine donor concentration was kept constant at 1
equivalent. Remarkably, complete molar conversion was achieved
with a residence time of just 5 min. Furthermore, a downstream
purification step to remove the acetophenone by-product, fol-
lowed by liquid–liquid extraction facilitated the isolation of the
final product with excellent yield (91%).While full conversion of
the starting material 1awas observed, the transamination reaction
did not take place selectively. In fact, a significant loss in ee was
observed with respect to the batch reactions (Table 2). A similar
phenomenon was also observed in the case of 2b. Although high
conversion of 2a was achieved after 10 mins of residence time,
the ee of the final product was 26% (S). Interestingly, these results
are much more comparable to those obtained in batch mode when
the tetrameric TA from Pseudomonas fluorescence was employed
as the biocatalyst. While the active sites of PfTA and HeWTwere
tary technologies that have enabled the intensification of indus-
trially relevant biocatalytic processes. In particular, the transfer
of enzyme-based processes into continuous flow is currently
the focus of growing attention.[9] While flow biocatalysis can be
performed using immobilised whole-cells or cell-free enzymes,
some excellent examples of cell-free reactions in continuous flow
have appeared in the literature in recent years.[10–12] For example,
our group were the first to report on the use of ω-transaminase
(ω-TA) in continuous flow for the synthesis of a panel of aromatic
amines.[13] The enzyme, which was covalently immobilised onto
a commercially available metal-derivatised epoxy resin proved to
be highly stable in a packed bed reactor (PBR) at high flow rates.
An in-line purification strategy was used, in which basification
of the reaction stream and extraction with ethyl acetate, afforded
the desired amine product. Traces of the unreacted aldehyde sub-
strate in the organic phase were effectively trapped using a ben-
zylamine functionalised resin. In addition excellent conversions
and reaction times were achieved compared to those obtained in
batch. Bearing this information in mind, we report herein on an
enzyme-based system for the synthesis of a series of small cyclic
molecules that are inherently difficult to produce using tradition-
al chemical methods. Furthermore, the application of flow bio-
catalysis in this case effectively demonstrates how biocatalytic
processes can easily be scaled-up, allowing for the direct, one-pot
conversion of inexpensive and readily available compounds to
high-value molecules, while also maintaining a very low envi-
ronmental impact.
Results and Discussion
Substrate Screening of Structurally Different ω-TAs
We started our studies on the sustainable formation of small
cyclic amines by selecting two structurally different ω-TAs from
our toolbox of enzymes, a dimericω-TA fromHalomonas elonga-
ta HeWT and a tetrameric ω-TA from Pseudomonas fluorescens
PfTA.[14,15] The previously reported screening forHeWTwith this
set of substrates[14] is given in Table 1 for comparison. 1a was
first employed on a 10 mM scale using 1 equivalent of (S)-ω-
methylbenzylamine, (S)-MBA, as the amine donor. Remarkably,
complete conversion to the corresponding amine 1bwas achieved
when HeWT was employed as the biocatalyst, whereas PfTA
reached a final conversion of ∼48.6%, possibly due to thermody-
namic limitations. Initial efforts to shift the equilibrium towards
product formation, by increasing the concentration of the amine
donor to 20 mM were successful, resulting in a final conversion
of 66.5% (Supplementary Information Table 3). However, fur-
ther improvements could not be achieved as precipitation of the
biocatalyst was observed at higher concentrations of (S)-MBA
(concentrations >20 mM). In terms of stereoselectivity, (S)-1b
was preferred in both cases, however the enantiomeric excess
was low for both TAs (HeWT, 70% (S); PfTA, 42% (S)). Given
the widespread occurrence of amino-substituted tetrahydrothio-
phenes, pyrrolidines and piperidines in pharmaceutically active
compounds, the substrate scope of HeWT and PfTA was further
probed with compounds 2a–4a.[16,17] Using the same reaction
conditions as outlined above, HeWT was able to transform the
selected compounds into the corresponding amines (2b–4b) with
excellent molar conversions. PfTA, on the other hand, afforded
moderate conversions in the case of compounds 2a and 4a, while
no conversion at all was detected in the case of 3a (Table 1).
Optimisation of the reaction conditions again proved challenging
due to the instability of the biocatalyst in the presence of high
concentrations of (S)-MBA. Regarding the stereoselectivity, com-
pound 2b was initially assumed to be S, in the absence of stand-
ards, by comparison with the other substrates.[14] This has been
recently re-evaluated by synthetic preparation of standards, to be,
in fact, R.[18] The same enantiomer was produced by HeWT and
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Further reaction optimisation was required in the case of com-
pounds 3a and 4a. High substrate loadings (50 mM) led to poor
molar conversions whichmay be attributed to substrate inhibition.
As a compromise, the flow reactions were performed on a 25 mM
scale using 1 equivalent of (S)-MBA as the amine donor. Longer
contact time with the biocatalyst (30–45 min) was required in
found to be very similar, the rigidity imposed by the additional
subunits make it more challenging for PfTA to effectively differ-
entiate between the α and α'-moieties flanking the carbonyl func-
tional group of compounds 1a and 2a. Similarly, the rigidification
imposed upon immobilisation ofHeWT is therefore thought to be
the main reason for this unusual loss in ee.


























98 90 (S) 17.6 >99 (S)
Molar conversions (m.c.), and enantiomeric excess (ee) for transaminase mediated conversion of tetrahydro-
furan-3-one (1a), tetrahydrothiophene-3-one (2a), 1-methylpyrrolidin-3-one (3a) and 1-methyl-piperidin-3-one
(4a). Final conversions were determined after 24 h of reaction. Biotransformations were performed with 10 mM
ketones, 1 equiv. (S)-(–)-α-methylbenzylamine, 0.1 mM PLP, 1 mg/mL enzyme in 50 mM phosphate buffer pH 8
at 37 °C (see Experimental details in Supplementary Information) 10 % (v/v) DMSO was used in the case of 2a
to improve solubility.
Table 1. Transaminase mediated
conversion of small cyclic prochi-
ral ketones (1a–4a) in batch mode
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support may be useful in minimising rigidification and retaining
catalytic activity upon immobilisation.[23] Nevertheless, this work
paves the way towards more sustainable and cost-effective manu-
facturing processes for an array of high value molecules.
Supplementary Information
Supplementary information is available on https://www.ingentacon-
nect.com/content/scs/chimia
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The reactions were performed in the presence of 25–50 mM ketone substrate (Solution A), 1 equiv. (S)-MBA
and 0.1 mM PLP (Solution B) in phosphate buffer (50 mM, pH 8.0). 10% (v/v) DMSO was used in the case of 2a
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